Neuroleptic malignant syndrome: Half a century of uncertainty suggests a Chimera

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 8, 2010, Pages 876-877

  Gillman, P Ken ^a  

^a PsychoTropical Research   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

EVIDENCE BASED MEDICINE; LETTER; MALIGNANT HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEROTONIN SYNDROME;

CAUSALITY; DOPAMINE ANTAGONISTS; HUMANS; MALIGNANT HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME; SEROTONIN SYNDROME; TIME FACTORS;

EID: 77956623396     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2008     Document Type: Letter

References (18)

1. Margetic B, Margetic BA. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf 2010. [Epub ahead of print].
2. Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions and causality. Mov Disord 2010: (in press).
3. Kellam AM. The neuroleptic malignant syndrome, so-called. A survey of the world literature. Br J Psychiatr 1987; 150: 752-759.
4. Levinson DF, Simpson GM. Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the 'neuroleptic malignant syndrome'. Arch Gen Psychiatr 1986; 43: 839-848.
5. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
6. Perrio M, Voss S, Shakir SA. Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance. Drug Saf 2007; 30: 333-346.
7. Gillman PK. Extracting value from case reports: lessons from Serotonin toxicity. Anaesthesia 2006; 61: 419-422.
8. Heyland D, Sauve M. Neuroleptic malignant syndrome without the use of neuroleptics. CMAJ 1991; 145: 817-819.
9. Isbister GK, Buckley NA. Clomipramine and neuroleptic malignant syndrome: literature on adverse reactions to psychotropic drugs continues to confuse. BMJ 2005; 330: 790-791.
10. Gillman PK. Understanding toxidromes: serotonin toxicity. A commentary on Montanes-Rada et al. J Clin Psychopharmacol 2005; 25: 625-626.
11. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998; 12: 482-491.
12. Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatr 2003; 160: 1233-1241.
13. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf 2009; 4: 84-93.
14. Factor SA, Santiago A. In Parkinsonism-Hyperpyrexia Syndrome in Parkinson's Disease, in Movement Disorder Emergencies: Diagnosis and Treatment, Frucht SJ, Fahn S (eds). 2005; Humana Press Inc: Totowa, NJ, 29-40.
15. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord 2001; 16: 960-962.
16. Toru M, Matsuda O, Makiguchi K, et al. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 1981; 169: 324-327.
17. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA 1985; 254: 2792-2795.
18. Gurrera RJ, Simpson JC, Tsuang MT. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatr 2007; 48: 205-211.